Hunger hormone levels in blood may reveal dementia type

NCT ID NCT05381090

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study investigates whether levels of the hormone ghrelin in the blood differ between people with various types of dementia, including Alzheimer's disease and dementia with Lewy bodies. Researchers will collect blood samples from 85 participants over age 60, both fasting and after eating, to measure ghrelin and related markers. The goal is to see if these measurements can help identify or distinguish different forms of dementia.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple blood test to help diagnose or distinguish different types of dementia earlier.
What could go wrong
This is a small, early-stage study that only measures biomarkers, not a treatment. The findings may not translate into a reliable diagnostic test.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

85 people

The number who actually took part.

Started

Aug 2022

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \> 60 years * Subject or carer / legal representative is willing to sign consent document Specific criteria for each group; Parkinson's Disease * PD diagnosed by a movement disorder specialist and meets the diagnosis of PD * MoCA \> 26/30 * No evidence of cognitive symptoms causing functional impairment Parkinson's Disease Dementia * PD diagnosed by a movement disorder specialist * Duration of motor symptoms \> 1 year * Meets MDS task force criteria for PDD * MoCA \< 21/30 Dementia with Lewy Bodies * Meets criteria for probable DLB as defined by the 4th report of the DLB consortium Alzheimer's Disease * Meets criteria for probable AD dementia (consistent with NIA/AA core clinical criteria for probable AD dementia) Exclusion Criteria: * Age \< 60 years * Current major depression * Use of anti-psychotic medication * Type I or Type II diabetes mellitus (DM) (excluding diet-controlled DM) * Tobacco use * BMI \<15.0 kg/m2 * BMI \> 30 kg/m2 * Comorbid gastrointestinal disease i.e. includes Coeliac, active Inflammatory Bowel Disease (Colitis), evidence for active gastric ulcers within the last 12 months, but excludes gastroesophageal reflux and hiatus hernia. * \>5 kg weight change over the preceding 3 months (determined by researcher from previous clinic visit and discussion with partner/carer) * Significant active comorbidity * Difficult venous access * Vagotomy Additional disease specific exclusions; * Parkinson's Disease exclusion criteria * Evidence of dementia or mild cognitive impairment * Deep brain stimulation (DBS) * Use of Duodopa Parkinson's Disease Dementia exclusion criteria * Dementia within 12 months of diagnosis of PD * DBS Dementia with Lewy bodies exclusion criteria * Onset of motor Parkinsonism symptoms greater than 12 months prior to dementia diagnosis Alzheimer's dementia exclusion criteria * Presence of PD, PDD, DLB, or Frontotemporal Dementia (FTD) Controls exclusion criteria * Evidence of parkinsonism * Evidence of dementia or mild cognitive impairment * MoCA \<26/30

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Swansea University

    Swansea, sa2 8pp, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.